Stock Price Quote

HESTER BIOSCIENCES LTD.

NSE : HESTERBIOBSE : 524669ISIN CODE : INE782E01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE2061.006.9 (+0.34 %)
PREV CLOSE ( ) 2054.10
OPEN PRICE ( ) 2067.40
BID PRICE (QTY) 2060.00 (1)
OFFER PRICE (QTY) 2077.30 (4)
VOLUME 636
TODAY'S LOW / HIGH ( )2052.65 2140.00
52 WK LOW / HIGH ( )1250.95 2347.7
NSE2059.907.3 (+0.36 %)
PREV CLOSE( ) 2052.60
OPEN PRICE ( ) 2052.70
BID PRICE (QTY) 2057.70 (2)
OFFER PRICE (QTY) 2062.00 (17)
VOLUME 7273
TODAY'S LOW / HIGH( ) 2039.30 2149.00
52 WK LOW / HIGH ( )1239.3 2350
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Bhupendra Gandhi - Chairman Rajiv Gandhi - Managing Director
Registered Office

Address Meda Adraj , Kadi, , ,
Mehsana,
Gujarat-384441

Phone 079 – 26445106

Email mail@hester.in

Website www.hester.in

Registrars Details
MUFG Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

18May Hester Biosciences informs about trans
Pursuant to Regulations 30 and 46(2)(oa) of the SEBI (Listing Obligation..
18May Hester Biosciences informs about news
In compliance with Regulation 30 of the SEBI (Listing Obligations and Di..
18May Hester Biosciences submits secretarial
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure R..
08Apr Hester Biosciences informs about compl
Hester Biosciences has informed that the details of securities demateria..
11Mar Hester Biosciences gets nod to divest
Hester Biosciences has received approval for the divestment of 43.81% eq..

Financials

in Millions
QTR Mar 26 ANNUAL 26
Net Profit263.84521
Gross Profit 348.7 696.82
Operating Profit 356.44801.07
Net Sales 937.132921.36

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26438.95 (1.88%)
M.Cap ( in Cr)55407.55
Neuland Laboratories (BSE)
peergroup  17175.85 (1.04%)
M.Cap ( in Cr)21948.22
Acutaas Chemicals (BSE)
peergroup  3137.90 (4.65%)
M.Cap ( in Cr)25584.73
Sanofi Cons. Health (BSE)
peergroup  4842.05 (1.94%)
M.Cap ( in Cr)11027.06
NGL Fine-Chem (BSE)
peergroup  3014.90 (2.95%)
M.Cap ( in Cr)1870.61

Shareholding Pattern

PROMOTERS 53.73%
NON-INSTITUTION 45.89%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Hester Biosciences Ltd.

Hester Biosciences Ltd. was incorporated in the year 1987. Its today's share price is 2061. Its current market capitalisation stands at Rs 1762.62 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2866.36 Cr and Total Income of Rs.2912.3 Cr. The company's management includes Vinod Mali, Jatin Trivedi, Anil Jain, Ameet Desai, Ashok Bhadakal, Sandhya Patel, Nina Gandhi, Sanjiv Gandhi, Priya Gandhi, Rajiv Gandhi, Bhupendra Gandhi.

It is listed on the BSE with a BSE Code of 524669 , NSE with an NSE Symbol of HESTERBIO and ISIN of INE782E01017. It's Registered office is at Meda Adraj , Kadi, , Mehsana-384441, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Apaji Amin & Co LLP, Chandulal M Shah & Co, Shah Karia & Associates, Shah Narielwala & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.